The preclinical pharmacodynamic and pharmacokinetic requirements for antiasthmatic drugs during compound development are outlined and discussed. The pharmacodynamics and pharmacokinetics should be characterized according to worldwide regulatory guidelines as well as a sound scientific basis. The relationship between the pharmacodynamic, pharmacokinetic, and toxicological data determines their relevance. Links between all sources of information are central to any presentation to regulatory authorities.
KaufmanLSSnoodyCS. Clinical study authorizations: Development strategies. Drug Inf J.1990;24: 549–559.
2.
Guidance notes on applications for clinical trial certificates and clinical trial exemptions. MAL 4, Annex 10, now included in MAL 2; 1989; Department of Health and Social Security.
3.
Richtlinie über die Prüfung von Arzneimitteln.Bundesanzeiger Nr. 113; Anhang 1/26; 25. Juni 1971.
4.
Recommendations for the characterization of the general pharmacodynamics of drugs.The rules governing medicinal products in the European Community. Vol. III./480/87 EN Rev 3; 3rd draft. Brussels: European Commission.
5.
Guidelines for General Pharmacology. Notification No.: Yakushinyaku No. 4. 1991; Japanese Ministry of Health and Welfare (MHW).
6.
Corticosteroids intended for use on the skin.The rules governing medicinal products in the European Community. Vol III; 1989; Catalogue no CB 55 89 293 EN-C. Brussels: European Community.
7.
Conduct of toxicity studies by inhalation.The rules governing medicinal products in the European Community. Vol III; 1989; Appendix B Vol III; Catalogue no CB 55 89 293 EN-C. Brussels: European Community.
8.
Drug Applications Nordic Guidelines. 2nd edition; March 1989. II F Pharmacodynamics. Nordic Council on Medicines, Uppsala, Sweden.
9.
The clinical investigation of drugs for the long term prophylactic management of asthma. Copenhagen: World Health Organization; 1988.
10.
DayanAD. New developments in Toxicology. In: BarnacalP ed. Pharmaceutical Manufacture International. London: Sterling Publishers Ltd.; 1991;85–86.
11.
Pharmacological and toxicological information.Federal Register. 1987;52, 53:§312.23;(a)(8).
12.
ScheupleinRJShoafSEBrownRN. Role of pharmacokinetics in safety evaluation and regulatory considerations. Annu Rev Pharmacol Tox. 1990;30: 197–218.
13.
Pharmacokinetics and metabolic studies in the safety evaluation of new drugs in animals.The rules governing medicinal products in the European Community. Vol III; 1989; Catalogue No CB-55–89-843-EN-C. Brussels: European Community.
14.
Preparation of investigational new drug submissions.Drugs Directorate Guidelines. Canada: Health Protection Branch; 1991.
15.
Guidelines for pharmacokinetic studies. Notification No.: Yakushinyaku No. 6. Japanese Ministry of Health and Welfare; 1991.
16.
DamaniLA. Metabolism of drugs in the respiratory tract. In: Drug delivery to the respiratory tract. GandertonDJonesTM, Eds. Chichester, United Kingdom: Ellis Horwood; 1987:47–59.
